Curon Medical's low stockholder equity falls foul of US stock market:
This article was originally published in Clinica
Executive Summary
Curon Medical, the Fremont, California company focused on treatment of gastrointestinal disorders, is facing possible delisting from the US Nasdaq stock exchange. The firm's stockholder equity, as of the end of 2005, was $2.2m, falling short of the minimum $2.5m stipulated by Nasdaq to remain listed on the exchange. Curon, which has seen its share price trading below $1 for nearly a year, is now required to provide by February 22 a plan for regaining market compliance.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.